Skip to content

A National, Multi-Center, Prospective Registry Study to Evaluate the Long-Term Safety and effectiveness of Roxadustat for Treatment of Anemia in Subjects with Chronic Kidney Disease (ROXSTAR Registry)

A National, Multi-Center, Prospective Registry Study to Evaluate the Long-Term Safety and effectiveness of Roxadustat for Treatment of Anemia in Subjects with Chronic Kidney Disease (ROXSTAR Registry)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046322
Enrollment
Unknown
Registered
2021-05-13
Start date
2020-10-20
Completion date
Unknown
Last updated
2022-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD anemia

Interventions

Case series:Nil

Sponsors

The First Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Subject has voluntarily signed and dated an informed consent form, approved by an Ethics Committee, after the nature of the study has been explained and the subject has had the opportunity to ask questions; 3. CKD anemia patients who are on Roxadustat (prevalent) treatment or could be treated by Roxadustat (incident) based on investigators judgement*. *Treatment should be performed after investigators careful assessment of the patient's risk/benefit. According to national CKD anemia treatment guidelines, hemoglobin level should be = 6 weeks.)

Exclusion criteria

Exclusion criteria: 1. Any other anemia caused by conditions other than CKD, e.g., thalassemia, sickle cell anemia, pure red cell aplasia, myelodysplastic syndrome, bleeding, malignancy etc. 2. Patients with medical history of serious drug allergy or known history of allergy to the active ingredients or excipients of Roxadustat; 3. Women who are pregnant or breastfeeding or women of childbearing potential who are not willing to use appropriate contraception; 4. Life expectancy of = 3 ULN and total bilirubin >= 2 ULN; (2) ALT or AST > 8 ULN; (3) Total bilirubin >= 5 ULN; 6. Patients who are participating in or will participate in an investigational interventional study during the study.

Design outcomes

Primary

MeasureTime frame
treatment-emergent adverse events;serious adverse events;adverse events of interest;Changes from baseline in vital signs, ECG findings, and selected clinical laboratory values;

Secondary

MeasureTime frame
Hemoglobin;SF-36 Vitality subscale score;SF-36 Physical Functioning subscale score;RAPA self-reported Physical Activity score;

Countries

China

Contacts

Public ContactJianghua Chen

The First Affiliated Hospital, College of Medicine, Zhejiang University

chenjianghua@zju.edu.cn+86 13905814085

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026